healthcare global enterprises has announced that the audio recording of its earnings call held with analysts and investors is now available. The call took place on May 20, 2026, to discuss the audited financial results for the quarter and year ended March 31, 2026.

The disclosure was made in compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously intimated the exchanges regarding the conduct of this earnings call.

The recording covers the standalone and consolidated financial performance of the company for the specified period. Investors and interested parties can access the audio file through the investor relations section of the company's website.

The link provided by the company for accessing the recording is https://www.hcgoncology.com/investor-relations/ . The intimation was signed by Sunu Manuel, Company Secretary & Compliance Officer.

Key Details

HealthCare Global Enterprises Limited has approved the divestment of its entire equity shareholding in BACC Health Care Private Limited to Inviga Healthcare Fund I and its nominee. The Board of Directors and Audit Committee granted approval during meetings held on May 19, 2026. The transaction is valued at INR 37,64,44,788 and is expected to be completed within 4-5 weeks from the date of the announcement, subject to the terms of the Share Purchase Agreement (SPA). BACC is engaged in fertility and reproductive healthcare services, which the company identified as a non-core business activity.

Transaction Details

The proposed transaction is a related party transaction, as the buyer, Inviga Healthcare Fund I, is controlled by Dr. B.S. Ajaikumar, the Promoter and Non-Executive Chairman of the company. The deal was approved following a competitive process. The company stated that the transaction is being undertaken on an arm's length basis, with the consideration based on a valuation report by an independent third-party valuer.

Financial Impact of BACC

For the financial year 2025-26, BACC reported revenue from operations of INR 60.45 crore, which accounted for 4.45% of the company's standalone revenue. The net worth of BACC as of March 31, 2026, stood at INR 17.53 crore, representing 1.09% of the company's standalone net worth. The divestment is expected to facilitate greater operational focus, allowing the company to reinvest capital in high-growth areas such as cancer services.

BACC Financial Metrics (FY 2025-26)

The following table summarises BACC's key financial metrics relative to HCG's standalone figures:

Payment Structure

The consideration of INR 37,64,44,788 will be paid in two tranches. An aggregate amount of INR 28,23,33,591 is payable on the date of closing. The remaining deferred consideration of INR 9,41,11,197 will be paid within 18 months of the signing of the SPA.